Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance

Boston Scientific CorporationTrade
ProShares UltraPro Short QQQ ETFTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs ProShares UltraPro Short QQQ ETF — how do they compare? Boston Scientific Corporation trades at $51.59 (market cap $74.19B), while ProShares UltraPro Short QQQ ETF trades at $37.39. The key difference: Boston Scientific Corporation is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.

BSXSQQQ
Market Cap
$74.19B
Sector
HealthLeveraged / Inverse
52-Week High
$108.14$92.95
52-Week Low
$42.63$36.31
Enterprise Value
$86.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

ProShares UltraPro Short QQQ ETF

SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $37.32, down 1.11% amid a bearish technical signal with moving averages indicating selling pressure. The ETF is designed to deliver -3x the daily performance of the Nasdaq-100, making it highly sensitive to tech sector volatility. Recent news highlights its role as a tactical hedge tool but warns of significant long-term erosion due to daily reset mechanics.

The outlook for SQQQ remains high-risk, suitable only for short-term hedging against Nasdaq declines. Key risks include volatility decay from daily leverage and dependency on precise market timing. Investor sentiment is cautious, with analysts emphasizing its unsuitability as a long-term holding despite potential tactical opportunities during tech selloffs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About ProShares UltraPro Short QQQ ETF

SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.

Read more on SQQQ